

Annex I

**Scientific conclusions and grounds for the variation to the terms of the Marketing
Authorisation(s)**

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for cefixime, the scientific conclusions are as follows:

In view of available data on encephalopathy from the literature and spontaneous reports including in some cases a close temporal relationship, a positive de-challenge and/or re-challenge and in view of a plausible mechanism of action, the PRAC considers a causal relationship between cefixime and encephalopathy is at least a reasonable possibility. The PRAC concluded that the product information of products containing cefixime should be amended accordingly.

Having reviewed the PRAC recommendation, the CMDh agrees with the PRAC overall conclusions and grounds for recommendation.

Grounds for the variation to the terms of the marketing authorisation(s)

On the basis of the scientific conclusions for cefixime the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing cefixime is unchanged subject to the proposed changes to the product information

The CMDh recommends that the terms of the marketing authorisation(s) should be varied.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike-through~~)

Summary of Product Characteristics

- Section 4.4

A warning should be added as follows:

Encephalopathy

Encephalopathy has been reported with the use of beta-lactam antibiotics including cefixime (see section 4.8 and 4.9), particularly in elderly patients and in patients with severe renal impairment or central nervous system disorders. If cefixime-associated encephalopathy is suspected discontinuation should be considered.

- Section 4.8

The following adverse reaction should be added under the SOC Nervous system disorders with a frequency not known:

Encephalopathy

- Section 4.9

There is a risk of encephalopathy associated with beta-lactam antibiotics such as cefixime, particularly in case of overdose.

Package Leaflet

Section 2 Warnings and precautions

Talk to your doctor or pharmacist before taking your medicine if:

....

-You have kidney or nervous system problems (see section 4)

Section 3

If you take higher dose of (name of the product) than you should, there is a risk of decreased consciousness, abnormal movements and convulsions.

.....

Section 4.

Treatment with cefixime, particularly in elderly patients or in patients with serious kidney or nervous system problems, has been known to cause decreased consciousness, movement disorders and convulsions (encephalopathy).

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	January 2026 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	15 March 2026
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	14 May 2026